FrancophonIA/ELRC3.0 huggingface dataset:
English: In healthy young adults (23 to 49 years of age), after intravenous infusion of radiolabelled 1 g ertapenem, the plasma radioactivity consists predominantly (94 %) of ertapenem.
Croatian: U zdravih mlađih odraslih osoba (u dobi od 23 do 49 godina), nakon intravenske infuzije doze od 1 g radioaktivno obilježenog ertapenema, radioaktivnost u plazmi sastoji se pretežno (94%) od ertapenema.
English: If you are concerned that you may have been given too much INVANZ, contact your doctor or another healthcare professional immediately.
Croatian: Ako se brinete da ste možda primili previše lijeka INVANZ, odmah se javite svom liječniku ili drugom zdravstvenom radniku.
English: In vitro studies indicate that ertapenem does not inhibit P-glycoprotein-mediated transport of digoxin or vinblastine and that ertapenem is not a substrate for P-glycoprotein-mediated transport.
Croatian: Istraživanja in vitro ukazuju da ertapenem ne inhibira transport digoksina i vinblastina posredovan P-glikoproteinom, kao i da ertapenem nije supstrat za transport posredovan P-glikoproteinom.
English: • Acute gynaecological infections
Croatian: • akutnih ginekoloških infekcija
English: Area under the plasma concentration curve (AUC) of ertapenem in adults increases nearly doseproportionally over the 0.5 to 2 g dose range.
Croatian: Površina ispod krivulje (AUC) koncentracije ertapenema u plazmi u odraslih povećava se gotovo proporcionalno dozi u rasponu doza od 0,5 do 2 g.
English: • Irregular heart rate, increased blood pressure, bleeding, fast heart rate
Croatian: • nepravilno kucanje srca, povišen krvni tlak, krvarenje, ubrzano kucanje srca
English: In vitro studies indicate that the effect of ertapenem on the plasma protein binding of highly protein bound medicinal products (warfarin, ethinyl estradiol, and norethindrone) was small.
Croatian: In vitro studije ukazuju da ertapenem ima malen učinak na vezivanje za proteine plazme onih lijekova koji se snažno vežu na te proteine (varfarin, etinilestradiol i noretindron).
English: Resistance can however be observed when ESBLs or other potent beta-lactamases (e.g. AmpC types) are present in conjunction with reduced permeability, arising by the loss of one or more outer membrane porins, or with up-regulated efflux.
Croatian: Rezistencija se, međutim, može uočiti kada je uz beta-laktamaze proširenog spektra ili druge snažne beta-laktamaze (npr. AmpC tipa) prisutna i ograničena propusnost za lijek uslijed gubitka jednog ili više porina na vanjskoj membrani ili povećan efluks.
English: Do not freeze solutions of INVANZ.
Croatian: Ne zamrzavati otopine lijeka INVANZ.
English: Following a single 1 g intravenous dose given immediately prior to a haemodialysis session, approximately 30 % of the dose is recovered in the dialysate.
Croatian: Nakon jednokratne intravenske doze od 1 g ertapenema primijenjene neposredno prije hemodijalize, otprilike 30% doze pronađeno je u dijalizatu.
English: Adults: To prevent surgical site infections following elective colorectal surgery, the recommended dosage is 1 g administered as a single intravenous dose to be completed within 1 hour prior to the surgical incision.
Croatian: Odrasli: Kako bi se spriječile infekcije operativnog područja nakon elektivnog kolorektalnog kirurškog zahvata, preporučeno doziranje je 1 g primijenjeno kao jednokratna intravenska doza koju treba završiti unutar 1 sata prije kirurške incizije.
English: Decreased neutrophil counts, however, occurred in rats that received high doses of ertapenem, which was not considered a significant safety issue.
Croatian: Međutim, kod štakora koji su primili visoke doze ertapenema zabilježen je snižen broj neutrofila, što se ne smatra značajnim rizikom za sigurnost primjene lijeka.
English: Compatibility of INVANZ with intravenous solutions containing heparin sodium and potassium chloride has been demonstrated.
Croatian: Dokazana je kompatibilnost lijeka INVANZ s otopinama za intravensku primjenu koje sadrže heparinnatrij i kalijev klorid.
English: • Pain at the infusion site
Croatian: • bol na mjestu infuzije
English: In clinical studies for the treatment of community-acquired pneumonia, in adults, 25 % of evaluable patients treated with ertapenem had severe disease (defined as pneumonia severity index > III).
Croatian: U kliničkim ispitivanjima liječenja izvanbolnički stečene pneumonije u odraslih osoba, 25% bolesnika liječenih ertapenemom koje je bilo moguće ocijeniti imalo je težak oblik bolesti (definiran kao indeks težine pneumonije >III).
English: In clinical studies in adults inadvertent administration of up to 3 g in a day did not result in clinically important adverse reactions.
Croatian: Kliničke studije u odraslih pokazale su da nenamjeran unos ertapenema do 3 g na dan ne izaziva klinički važne nuspojave.
English: Rare: Neutropenia, thrombocytopenia
Croatian: Rijetko: neutropenija, trombocitopenija
English: Hepatic impairment No dosage adjustment is recommended in patients with impaired hepatic function (see section 5.2).
Croatian: Ne preporučuje se prilagodba doze u bolesnika s oštećenjem funkcije jetre (vidjeti dio 5.2).
English: This includes 9 patients in the ertapenem group (7 CAP and 2 IAI), 2 patients in the ceftriaxone group (2 CAP), and 1 patient with IAI in the ticarcillin/clavulanate group with secondary bacteraemia at entry into the study.
Croatian: Obuhvaća 9 bolesnika iz skupine na ertapenemu (7 s izvanbolnički stečenom pneumonijom i 2 s intraabdominalnom infekcijom), 2 bolesnika iz skupine na ceftriaksonu (oba s izvanbolnički stečenom pneumonijom) te 1 bolesnika iz skupine na tikarcilinu/klavulanatu s intraabdominalnom infekcijom koji su prilikom ulaska u ispitivanje imali sekundarnu bakterijemiju.
English: Plasma concentrations following a 1 g and 2 g intravenous dose of ertapenem are slightly higher (approximately 39 % and 22 %, respectively) in healthy elderly adults (≥ 65 years) relative to young adults ( 65 years).
Croatian: Koncentracije u plazmi nakon primjene intravenske doze od 1 g i 2 g nešto su više (približno 39%, odnosno 22%) u zdravih starijih osoba (≥ 65 godina), u odnosu na mlađe odrasle osobe (65 godina).
English: Not known: Altered mental status (including aggression, delirium, disorientation, mental status changes)
Croatian: Nepoznato: promijenjeno psihičko stanje (uključujući agresivnost, delirij, dezorijentiranost, promjene psihičkog stanja)
English: Tell your doctor if you are taking medicines called valproic acid or sodium valproate (see Other medicines and INVANZ below).
Croatian: Obavijestite liječnika ako uzimate lijekove koji se zovu valproatna kiselina ili natrijev valproat. (pogledajte Drugi lijekovi i INVANZ u daljnjem tekstu).
English: In healthy young adults (18 to 49 years of age) and patients 13 to 17 years of age given a 1 g intravenous dose, the mean plasma half-life is approximately 4 hours.
Croatian: U zdravih mlađih osoba (u dobi od 18 do 49 godina) i u bolesnika od 13 do 17 godina koji su primili intravensku dozu od 1 g, prosječno poluvrijeme u plazmi iznosi otprilike 4 sata.
English: Each vial contains 1.0 g ertapenem.
Croatian: Jedna bočica sadrži 1,0 g ertapenema.
English: • Decrease in white blood cells, decrease in blood platelet count
Croatian: • snižen broj bijelih krvnih stanica, snižen broj krvnih pločica
English: Uncommon: Insomnia, confusion Rare: Agitation, anxiety, depression
Croatian: Manje često: nesanica, konfuzija Rijetko: agitiranost, anksioznost, depresija
English: Not known: Altered mental status (including aggression)
Croatian: Nepoznato: promjene mentalnog stanja (uključujući agresivnost)
English: Uncommon: Anorexia Rare: Hypoglycaemia
Croatian: Manje često: anoreksija Rijetko: hipoglikemija
English: Pharmacokinetic/Pharmacodynamic (PK/PD) relationship Similar to other beta-lactam antimicrobial agents, the time that the plasma concentration of ertapenem exceeds the MIC of the infecting organism has been shown to best correlate with efficacy in pre-clinical PK/PD studies.
Croatian: Farmakokinetički/farmakodinamički (PK/PD) odnos Slično kao i kod drugih beta-laktamskih antibiotika, pretkliničke studije farmakokinetike i farmakodinamike pokazale su da vrijeme tijekom kojega je koncentracija ertapenema u plazmi viša od minimalne inhibicijske koncentracije (MIK) za danog uzročnika najbolje odgovara njegovoj djelotvornosti.
English: Adverse reactions (i.e., considered by the investigator to be possibly, probably, or definitely related to the medicinal product) were reported in approximately 20 % of patients treated with ertapenem.
Croatian: Nuspojave (tj. one reakcije čiju je povezanost s lijekom ispitivač smatrao mogućom, vjerojatnom ili sigurnom) su prijavljene u približno 20% bolesnika liječenih ertapenemom.
English: Uncommon: Sinus bradycardia Rare: Arrhythmia, tachycardia
Croatian: Manje često: sinusna bradikardija Rijetko: aritmija, tahikardija
English: General properties
Croatian: Opća svojstva
English: The volume of distribution (Vdss) of ertapenem in adults is approximately 8 litres (0.11 litre/kg) and approximately 0.2 litre/kg in paediatric patients 3 months to 12 years of age and approximately 0.16 litre/kg in paediatric patients 13 to 17 years of age.
Croatian: Volumen distribucije (Vdss) ertapenema iznosi približno 8 litara (0,11 l/kg) u odraslih osoba, približno 0,2 l/kg u djece od 3 mjeseca do 12 godina te približno 0,16 l/kg u pedijatrijskih bolesnika u dobi od 13 do 17 godina.
English: In a clinical study for the treatment of acute gynaecologic infections, in adults, 26 % of evaluable patients treated with ertapenem had severe disease (defined as temperature ≥ 39C and/or bacteraemia); ten patients had bacteraemia.
Croatian: U kliničkom ispitivanju liječenja akutnih ginekoloških infekcija u odraslih osoba, 26% bolesnica koje je bilo moguće ocijeniti i koje su liječene ertapenemom imalo je težak oblik infekcije (definirano kao tjelesna temperatura ≥ 39°C i/ili bakterijemija); u deset bolesnica ustanovljena je bakterijemija.
English: When clinically indicated, a switch to an appropriate oral antibacterial agent may be implemented if clinical improvement has been observed.
Croatian: Ako je to klinički indicirano, nakon kliničkog poboljšanja može se prijeći na odgovarajući peroralni antibiotik.
English: The active ingredient of INVANZ is ertapenem 1 g.
Croatian: Djelatna tvar u lijeku INVANZ je ertapenem 1 g.
English: How to use INVANZ
Croatian: Kako čuvati INVANZ
English: In healthy young adults (25 to 45 years of age), the protein binding of ertapenem decreases, as plasma concentrations increase, from approximately 95 % bound at an approximate plasma concentration of < 50 micrograms/mL to approximately 92 % bound at an approximate plasma concentration of 155 micrograms/mL (average concentration achieved at the end of infusion following 1 g intravenously).
Croatian: U zdravih mlađih odraslih osoba (u dobi od 25 do 45 godina) vezanje ertapenema na proteine smanjuje se s povećanjem koncentracije u plazmi, i to sa otprilike 95% vezanja pri približnoj koncentraciji od < 50 mikrograma/ml do približno 92% vezanog ertapenema pri koncentraciji od oko 155 mikrograma/ml (prosječna koncentracija postignuta na kraju intravenske infuzije od 1 g).
English: There are no data in children and adolescents with renal impairment.
Croatian: Nema podataka o primjeni u djece i adolescenata s oštećenjem bubrega.
English: In this age group, particular care should be taken to establish the susceptibility of the infecting organism(s) to ertapenem.
Croatian: U ovoj dobnoj skupini s osobitom pozornošću treba utvrditi osjetljivost uzročnika infekcije na ertapenem.
English: Sodium bicarbonate (E500); sodium hydroxide (E524) to adjust pH to 7.5.
Croatian: Natrijev hidrogenkarbonat (E500); natrijev hidroksid (E524) za prilagodbu pH na 7,5.
English: INVANZ may influence patients' ability to drive and use machines.
Croatian: INVANZ može utjecati na sposobnost upravljanja vozilima i rada sa strojevima.
English: Common: Infused vein complication, phlebitis/thrombophlebitis Uncommon: Hypotension Rare: Haemorrhage, increased blood pressure
Croatian: Često: komplikacije na veni u koju je davana infuzija, flebitis/tromboflebitis Manje često: hipotenzija Rijetko: hemoragija, povišen krvni tlak
English: • Changes in white blood cell count
Croatian: • promjene broja bijelih krvnih stanica
English: How to store INVANZ
Croatian: Kako primjenjivati INVANZ
English: At the 15 mg/kg dose, the AUC value and plasma concentrations at the midpoint of the dosing interval in patients 3 months to 12 years of age were comparable to those in young healthy adults receiving a 1 g intravenous dose of ertapenem.
Croatian: Kod primjene doze od 15 mg/kg, AUC i koncentracije lijeka u plazmi na polovici intervala doziranja u djece od 3 mjeseca do 12 godina starosti bili su usporedivi s onima u zdravih mlađih odraslih osoba koje su primile jednu intravensku dozu od 1 g ertapenema.
English: For patients who received only INVANZ, the following adverse reactions were reported during therapy plus follow-up for 14 days after treatment was stopped:
Croatian: U bolesnika koji su primali samo INVANZ, za vrijeme terapije i praćenja tijekom 14 dana nakon prestanka liječenja prijavljene su sljedeće nuspojave:
English: Common: Rash, pruritus Uncommon: Erythema, urticaria Rare: Dermatitis, desquamation Not known: Acute Generalised Exanthematous Pustulosis (AGEP), Drug Rash with Eosinophilia and Systemic Symptoms (DRESS syndrome)
Croatian: Često: osip, svrbež Manje često: eritem, urtikarija Rijetko: dermatitis, deskvamacija Nepoznato: akutna generalizirana egzantematozna pustuloza (AGEP), kožni osip uzrokovan lijekom s eozinofilijom i sistemskim simptomima (DRESS sindrom)
English: • Skin infections of the foot in diabetic patients.
Croatian: • infekcije kože stopala u bolesnika koji imaju šećernu bolest.
English: There is no experience in children under 3 months of age.
Croatian: Nema iskustva s primjenom u djece mlađe od 3 mjeseca.
English: This medicine contains approximately 6.0 mEq (approximately 137 mg) of sodium per 1.0 g dose which should be taken into consideration by patients on a controlled sodium diet.
Croatian: Ovaj lijek sadrži približno 6,0 mEq (približno 137 mg) natrija po dozi od 1,0 g, o čemu treba voditi računa u bolesnika s ograničenjem unosa natrija.
English: • Dizziness, sleepiness, sleeplessness, confusion, seizure
Croatian: • omaglica, pospanost, nesanica, smetenost, napadaji
English: The reconstituted solution should be diluted in sodium chloride 9 mg/mL (0.9 %) solution immediately after preparation.
Croatian: Rekonstituirana otopina mora se razrijediti u otopini natrijevog klorida 9 mg/ml (0,9%) neposredno nakon pripreme.
English: Porphyromonas asaccharolytica*
Croatian: Porphyromonas asaccharolytica* vrste roda Prevotella*
English: Resistance is uncommon in Enterobacteriaceae and ertapenem is generally active against those with extended-spectrum beta-lactamases (ESBLs).
Croatian: Rezistencija je manje česta kod roda Enterobacteriaceae, tako da je ertapenem generalno djelotvoran protiv onih vrsta koje luče beta-laktamaze proširenog spektra.
English: Rare: Muscle cramp, shoulder pain
Croatian: Rijetko: grčevi u mišićima, bol u ramenu
English: A comparison of results show that a 1 g once daily dose of ertapenem achieves a pharmacokinetic profile in patients 13 to 17 years of age comparable to that of adults.
Croatian: Usporedba rezultata pokazuje da ertapenem u dozi od 1 g na dan u djece od 13 do 17 godina postiže sličan farmakokinetički profil kao u odraslih osoba.
English: • Gynaecological infections
Croatian: • ginekološke infekcije
English: Infants and children (3 months to 12 years of age): The dose of INVANZ is 15 mg/kg given twice daily (not to exceed 1 g/day) by the intravenous route (see section 6.6).
Croatian: Dojenčad i djeca (3 mjeseca do 12 godina): Doza lijeka INVANZ je 15 mg/kg dvaput na dan (ne smije prijeći 1 g na dan), primijenjeno intravenskim putem (vidjeti dio 6.6).
English: Side effects reported rarely (more than 1 in 10,000 patients and less than 1 in 1,000 patients) are:
Croatian: Rijetko prijavljene nuspojave (više od 1 na 10 000 bolesnika i manje od 1 na 1000 bolesnika) su:
English: Ertapenem is highly bound to human plasma proteins.
Croatian: Ertapenem se snažno veže na proteine u ljudskoj plazmi.
English: Each vial contains: 1.0 g ertapenem (as sodium).
Croatian: Jedna bočica sadrži: 1,0 g ertapenema (u obliku ertapenemnatrija).
English: Following administration of a 1 g radiolabelled intravenous dose of ertapenem to healthy young adults (23 to 49 years of age), approximately 80 % is recovered in urine and 10 % in faeces.
Croatian: Nakon primjene radioaktivno obilježene intravenske doze od 1 g ertapenema u zdravih mlađih odraslih osoba (u dobi od 23 do 49 godina) približno 80% se pronađe u mokraći, a 10% u fecesu.
English: The most common (more than 1 in 100 patients and less than 1 in 10 patients) side effects are:
Croatian: Najčešće nuspojave (više od 1 na 100 bolesnika i manje od 1 na 10 bolesnika) su:
English: INVANZ contains sodium
Croatian: INVANZ sadrži natrij
English: Following a single 1 g intravenous dose of ertapenem in adults, AUCs of total ertapenem (bound and unbound) and of unbound ertapenem are similar in patients with mild renal impairment (Clcr 60 to 90 mL/min/1.73 m2) compared with healthy subjects (ages 25 to 82 years).
Croatian: Nakon jednokratne intravenske doze od 1 g ertapenema, AUC ukupnog ertapenema (vezanog i nevezanog) kao i AUC nevezanog ertapenema u bolesnika s blagim oštećenjem funkcije bubrega (Clcr 60 do 90 ml/min/1,73 m2) slični su onima u zdravih ispitanika (u dobi od 25 do 82 godine).
English: • Changes in some laboratory blood tests
Croatian: • promjene u nalazima nekih laboratorijskih pretraga krvi
English: It is important that you tell your doctor if you are pregnant or are planning to become pregnant before receiving INVANZ.
Croatian: Važno je da prije nego primite INVANZ obavijestite liječnika ako ste trudni ili planirate trudnoću.
English: No data are available in children under 3 months of age.
Croatian: Nema podataka o primjeni u djece mlađe od 3 mjeseca.
English: Concentrations of ertapenem achieved in adult skin blister fluid at each sampling point on the third day of 1 g once daily intravenous doses showed a ratio of AUC in skin blister fluid: AUC in plasma of 0.61.
Croatian: Koncentracije ertapenema u tekućini iz mjehurića na koži u odraslih pri svakom su uzimanju uzorka trećeg dana liječenja intravenskom dnevnom dozom od 1 g ertapenema pokazivale omjer između AUC-a u tekućini iz kože: AUC-a u plazmi od 0,61.
English: A clinically significant interaction due to ertapenem displacing another medicinal product or another medicinal product displacing ertapenem is unlikely.
Croatian: Nije vjerojatna klinički značajna interakcija uslijed toga što bi ertapenem istisnuo drugi lijek s mjesta vezanja, ili obrnuto.
English: Species for which acquired resistance may be a problem:
Croatian: Vrste kod kojih stečena rezistencija može predstavljati problem: Gram-pozitivni aerobi:
English: Side effects reported (frequency not known) since the drug has been marketed are:
Croatian: Nuspojave prijavljene nakon stavljanja lijeka u promet (čija je učestalost nepoznata) su:
English: Ertapenem is excreted in human milk.
Croatian: Ertapenem se izlučuje u majčino mlijeko.
English: Rare: Cholecystitis, jaundice, liver disorder
Croatian: Rijetko: kolecistitis, žutica, poremećaj jetre
English: Clostridium species (excluding C. difficile)* Eubacterium species*
Croatian: Anaerobi: vrste roda Clostridium (osim C. difficile)* vrste roda Eubacterium* vrste roda Fusobacterium* vrste roda Peptostreptococcus*
English: The EUCAST MIC breakpoints are as follows:
Croatian: Europski odbor za testiranje osjetljivosti na antibiotike (EUCAST) utvrdio je sljedeće granične vrijednosti MIK-a:
English: Sodium bicarbonate (E500) Sodium hydroxide (E524) to adjust pH to 7.5
Croatian: 6.1 Popis pomoćnih tvari natrijev hidrogenkarbonat (E500) natrijev hidroksid (E524) za prilagodbu pH na 7,5
English: Average concentrations of ertapenem in urine exceed 984 micrograms/mL during the period 0 to 2 hours postdose and exceed 52 micrograms/mL during the period 12 to 24 hours post-administration.
Croatian: Prosječna koncentracija ertapenema u mokraći premašuje 984 mikrograma/ml tijekom razdoblja od 0 do 2 sata nakon doze te 52 mikrograma/ml u razdoblju od 12 do 24 sata nakon davanja lijeka.
English: Uncommon: Hot flush, hypertension
Croatian: Manje često: navale vrućine, hipertenzija
English: Therefore, no dosage adjustment is recommended in patients with hepatic impairment.
Croatian: Stoga se ne preporučuje prilagodba doze u bolesnika s oštećenjem funkcije jetre.
English: Rare: Decreases in serum bicarbonate, serum creatinine, and serum potassium; increases in serum LDH, serum phosphorus, serum potassium
Croatian: Rijetko: snižene vrijednosti bikarbonata, kreatinina i kalija u serumu; povišene vrijednosti LDH-a, fosfora i kalija u serumu
English: In this age group your doctor will decide on the potential benefit of its use.
Croatian: Liječnik će odlučiti o mogućoj koristi liječenja ovim lijekom u toj dobnoj skupini.
English: • Skin redness, skin rash
Croatian: • crvenilo kože, osip kože
English: Plasma concentrations at the midpoint of the dosing interval following a single 15 mg/kg intravenous dose of ertapenem in patients 3 months to 12 years of age are comparable to plasma concentrations at the midpoint of the dosing interval following a 1 g once daily intravenous dose in adults (see Plasma concentrations).
Croatian: Koncentracije ertapenema u plazmi na polovici intervala doziranja u bolesnika u dobi od 3 mjeseca do 12 godina nakon jednokratne intravenske doze od 15 mg/kg bile su usporedive s koncentracijama u plazmi na polovici intervala doziranja u odraslih osoba nakon intravenske doze od 1 g na dan (vidjeti Koncentracije u plazmi).
English: Less common (more than 1 in 1,000 patients and less than 1 in 100 patients) side effects are:
Croatian: Manje česte nuspojave (više od 1 na 1000 bolesnika i manje od 1 na 100 bolesnika) su:
English: • Skin redness
Croatian: • crvenilo kože
English: The reconstituted solutions should be inspected visually for particulate matter and discolouration prior to administration, whenever the container permits.
Croatian: Prije primjene rekonstituirane otopine potrebno je provjeriti moguću prisutnost čestica i promjenu boje kad god je to moguće s obzirom na spremnik.
English: • Burning, itching, redness and warmth at infusion site, redness at injection site
Croatian: • pečenje, svrbež, crvenilo i toplina na mjestu infuzije, crvenilo na mjestu injekcije
English: • Changes in some laboratory blood and urine tests
Croatian: • promjene u nalazima nekih laboratorijskih pretraga krvi i mokraće
English: • teeth staining
Croatian: • mrlje na zubima
English: Uncommon: Oral candidiasis, candidiasis, fungal infection, pseudomembranous enterocolitis, vaginitis
Croatian: Manje često: oralna kandidijaza, kandidijaza, gljivična infekcija, pseudomembranozni enterokolitis, vaginitis
English: There is no target-based cross-resistance between ertapenem and these substances.
Croatian: Između ertapenema i ovih tvari nema križne rezistencije povezane s mjestom djelovanja.
English: The plasma clearance (mL/min/kg) of ertapenem in patients 3 months to 12 years of age is approximately 2-fold higher as compared to that in adults.
Croatian: Klirens ertapenema iz plazme (ml/min/kg) u bolesnika od 3 mjeseca do 12 godina starosti bio je oko dva puta veći nego u odraslih.
English: Reconstitute the contents of a 1 g vial of INVANZ with 10 mL of water for injection or sodium chloride 9 mg/mL (0.9 %) solution to yield a reconstituted solution of approximately 100 mg/mL.
Croatian: Rekonstituirajte sadržaj jedne bočice lijeka INVANZ od 1 g u 10 ml vode za injekcije ili otopine natrijevog klorida od 9 mg/ml (0,9%), kako biste dobili rekonstituiranu otopinu koncentracije približno 100 mg/ml.
English: Common: Diaper dermatitis Uncommon: Erythema, rash, petechiae
Croatian: Često: pelenski dermatitis Manje često: eritem, osip, petehije
English: Therefore, ertapenem should not be used in these patients.
Croatian: Stoga se tim bolesnicima ne bi trebao davati ertapenem.